Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221845 | 0.92 | ADORA2A (0.55) | ADORA2AADORA1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8217493 | 0.91 | ADORA2A (0.54) | ADORA2AADORA1 | |
| SCHEMBL8223855 | 0.91 | ADORA2A (0.64) | ADORA2AADORA1 | |
| SCHEMBL8223871 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1 | |
| SCHEMBL13368130 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1 | |
| SCHEMBL8220368 | 0.88 | ADORA2A (0.52) | ADORA2AADORA1ALDH1A1 | |
| SCHEMBL8217490 | 0.88 | ADORA2A (0.52) | ADORA2AADORA1 | |
| SCHEMBL13341606 | 0.88 | KMT2A (0.54) | ADORA2AADORA1 | |
| SCHEMBL8225409 | 0.88 | ADORA2A (0.52) | ADORA2AADORA1 | |
| SCHEMBL8226536 | 0.88 | ADORA2A (0.51) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713985-B2 | Adenosine Aa2 receptor antagonists | SCHERING CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713985-B2 | Adenosine Aa2 receptor antagonists | SCHERING CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2038285-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| WO-2008002596-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885RAB9A 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.